MKI67 and cancer: Among the MKShi/ERSlo cancers, 21 out of 42 (50%) had Ki67 > 10% at surgery, whereas only 10 out of 41 (24.4%) MKShi/ERShi cancers showed similar high Ki67 levels, indicating lower responsiveness to endocrine therapy in MKShi/ERSlo cancers.